SELECTIVE T CELL CO-STIMULATION
MODULATORS, AN IMPROVED THERAPEUTIC
APPROACH OVER CALCINEURIN INHIBITORS
IN IMMUNOSUPPRESSIVE DRUG THERAPY.
MARIAN SORIN PAVELIU*
"Titu Maiorescu" University, Faculty of Medicine and Dentistry,
Department of Pharmacology, Bucharest, Romania
*corresponding author: sorinpaveliu@yahoo.com
Download Full Article

Abstract:

Transplant tolerance is an important issue in the clinical practice. Successful transplant depends on the ability to block the rejection of the transplanted organ. Currently, improving transplant tolerance is accomplished using immunosuppressive agents, but having also many toxic effects on the host body. So far, the conventional immunosuppressive therapy with calcineurin inhibitors such as cyclosporine or the newer tacrolimus, is the most common way to treat and prevent rejection; but, since the appearance of the fusion proteins, it became clear that the transplanted patients might have a chance for life-on-therapy but without the many toxic effects of the conventional immunosuppressive therapy.
This new drug category - co-stimulation blockers - have the potential to eventually replace current therapies to become the new standard therapy of immunosuppression after organ transplantation.

Top